- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT05536752
QA102 Fase II-studie i forsøkspersoner med tørr AMD (AMEND)
En fase 2, dobbeltmasket, randomisert, placebokontrollert, dose-respons-studie som vurderer sikkerheten og effekten av QA102 hos personer med tørr aldersrelatert makuladegenerasjon (AMD)
This is a phase 2, double-masked, randomized, placebo-controlled, dose-response study. The primary objective of the study is to evaluate the efficacy of QA102 oral capsules on the development of soft drusen, visual acuity (VA), and geographic atrophy (GA) or choroidal neovascularization (CNV) or the progression of GA in subjects with intermediate to advanced dry AMD.
Studieoversikt
Status
Intervensjon / Behandling
Detaljert beskrivelse
Approximately 30 sites will randomize a total of approximately 150 subjects to 1 of 3 treatment arms in a 1:1:1 ratio (50 subjects per arm). Each subject will receive either QA102 or matching placebo BID for up to 15 months.
Studietype
Registrering (Faktiske)
Fase
- Fase 2
Kontakter og plasseringer
Studiesteder
-
-
Arizona
-
Phoenix, Arizona, Forente stater, 85021
- Associated Retina Consultants
-
-
California
-
Mountain View, California, Forente stater, 94040
- Northern California Retina Vitreous Associates Medical Group
-
Pasadena, California, Forente stater, 91107
- California Eye Specialists Medical Group
-
Redlands, California, Forente stater, 91107
- California Eye Specialists Medical Group
-
-
Colorado
-
Colorado Springs, Colorado, Forente stater, 80909
- Retina Consultants of Southern Colorado, P.C.
-
-
Florida
-
Deerfield Beach, Florida, Forente stater, 33064
- Advanced Research
-
Fort Myers, Florida, Forente stater, 33912
- National Ophthalmic Research Institute
-
Miami, Florida, Forente stater, 33143
- MedEye Associates
-
Pensacola, Florida, Forente stater, 32503
- Retina Specialty Institute
-
Pinellas Park, Florida, Forente stater, 33782
- Eye Associates of Pinellas
-
Sarasota, Florida, Forente stater, 34239
- Sarasota Retina Institute
-
Winter Haven, Florida, Forente stater, 33880
- Vitreous and Retina Consultants
-
-
Georgia
-
Marietta, Georgia, Forente stater, 30060
- Marietta Eye Clinic
-
-
Illinois
-
Oak Forest, Illinois, Forente stater, 60452
- University Retina and Macula Associates
-
-
Louisiana
-
West Monroe, Louisiana, Forente stater, 71291
- Northeast Louisiana dba Haik Humble Eye Center
-
-
Maryland
-
Baltimore, Maryland, Forente stater, 21209
- The Retina Care Center
-
Hagerstown, Maryland, Forente stater, 21740
- Cumberland Valley Retina Consultants
-
Hagerstown, Maryland, Forente stater, 21740
- Mid Atlantic Retina Specialists
-
-
Massachusetts
-
Worcester, Massachusetts, Forente stater, 01605
- Vitreo-Retinal Associates, P.C.
-
-
Missouri
-
St Louis, Missouri, Forente stater, 63144
- Retina Research Institute
-
-
Ohio
-
Cincinnati, Ohio, Forente stater, 45202
- Velocity Clinical Research
-
-
Oregon
-
Eugene, Oregon, Forente stater, 97401
- Verum Research, LLC
-
-
Pennsylvania
-
Erie, Pennsylvania, Forente stater, 16507
- Erie Retina Research
-
-
Texas
-
Abilene, Texas, Forente stater, 79606
- Retina Research Institute of Texas
-
Austin, Texas, Forente stater, 78705
- Austin Research Center for Retina
-
Dallas, Texas, Forente stater, 75243
- AXIS Clinicals LLC / Retina of North Texas
-
Plano, Texas, Forente stater, 75075
- Texas Retina Associates - Plano
-
San Antonio, Texas, Forente stater, 78215
- San Antonio Eye Center
-
-
Utah
-
Salt Lake City, Utah, Forente stater, 84107
- Rocky Mountain Retina Consultants
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Key Inclusion Criteria:
- Subject must be able to understand and willing to sign a written informed consent form (ICF) prior to the initiation of any study-specific procedures.
- Subject must be age ≥50 years at the time of informed consent.
- Subject must be able to take oral medications and willing to record daily adherence to taking their assigned capsules.
- Subject must have adequate hematologic function, hepatic function, renal function and coagulation profile as defined in the protocol.
- Subject must be willing and able to comply with study procedures and examinations.
Specific to the Study Eye:
-
Subject must have one of the following:
- extensive intermediate-size drusen, or at least 1 large drusen, or
- GA ((not involving the foveal center point) secondary to AMD, with very limited aggregate size of total GA(s), as defined in the protocol.
-
Subject must be able to correctly identify ≥35 ETDRS letters (approximately 20/200 Snellen equivalent).
Specific to Fellow Eye:
- Subject must have a diagnosis of advanced AMD (evidence of GA and/or CNV), to be confirmed by the CRC.
Specific to Both Eyes:
- Subject must have visualizable retina, clear ocular media, and adequate pupillary dilation to ensure high-quality fundus imaging.
Key Exclusion Criteria:
- Subject received an active investigational drug within 6 weeks (or 5 half-lives of the active, whichever is longer) prior to screening for this QA102 study.
- Subject has ever received gene therapy (for any condition).
- Subject is unwilling to stop intake of Age-Related Eye Disease Studies (AREDS) vitamins for the duration of the study.
- Subject has a clinically significant systemic disease that might interfere with the study, in the judgment of the Investigator.
- Subject had major surgery within 30 days prior to Screening.
Specific to Study Eye:
- Subject has large GA, subfoveal GA, or active or inactive CNV, as confirmed by the CRC.
- Subject has GA or CNV due to causes other than AMD that that developed between Visit 1 (Screening) and Visit 2 (Randomization).
- Subject has endophthalmitis.
- Subject has a hemorrhagic or serous pigment epithelial detachment (PED) within 500 µm of the foveal center point, to be confirmed by the CRC.
- Subject has had retinal procedures or surgeries, or has a retinal pathology, such as a macular hole.
- Subject has aphakia or absence of the posterior capsule.
- Subject has ever received, whether in an interventional trial or by prescription, an FDA- approved treatment for GA. Use of such treatment during the QA102 study period also is prohibited. (Study Eye Only)
Specific to Fellow Eye:
Subject has monocular vision impairment, defined as having no light perception in the fellow eye with adequate vision in the study eye.
Specific to Either Eye:
- Subject had intraocular surgery with lens replacement within 3 months of Screening.
- Subject has any ophthalmic condition that could require surgery during the study period.
- Subject has an ocular condition that might affect adequate imaging of the retina and/or or alter visual acuity.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Trippel
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: QA102 200mg group
Subjects randomized to this arm will receive one (1) 200 mg capsule of QA102 and 1 placebo capsule BID = daily dose of 400 mg QA102 for up to 15 months |
Capsules |
|
Eksperimentell: QA102 400mg group
Subjects randomized to this arm will receive two (2) 200 mg capsules of QA102 BID = daily dose of 800 mg QA102 for up to 15 months |
Capsules |
|
Placebo komparator: Placebo group
Subjects randomized to this arm will receive two (2) placebo capsules BID = daily dose of 0 mg QA102 for up to 15 months |
Capsules |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Change From Baseline in Soft Drusen Volume (mm3)
Tidsramme: Month 12
|
Change from baseline in soft drusen volume (mm3), Efficacy-Evaluable Analysis Set |
Month 12
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Mean Rate of GA Growth
Tidsramme: Month 12
|
Mean Rate of Growth in GA (mm2) (Square Root Transformation) from Baseline |
Month 12
|
Samarbeidspartnere og etterforskere
Sponsor
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Faktiske)
Studiet fullført (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Andre studie-ID-numre
- QA102-CS201
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .